After six weeks of pembrolizumab treatment, patients with advanced melanoma expressing BRAF V600E/K were randomized, as part of the phase 2 IMPemBra trial, to continue pembrolizumab alone or added dabrafenib plus trametinib (two cohorts of intermittent dosing and a cohort of continuous dosing for six weeks). This evidence concerns the gene BRAF and melanoma.